skip to main
For US Healthcare Professionals Only
Image of a blueprint of the Mona Lisa with text overlay 'Looking deeper into the management of DDLPS'.

Looking deeper into 
the management of 
DDLPS

DDLPS=dedifferentiated liposarcoma.

There are limited systemic therapies for patients with advanced or metastatic disease

  • Surgery is the primary treatment for early-stage DDLPS1,2

  • Surgery for retroperitoneal sarcomas can be challenging due to the potential size of the tumor, as well as the close proximity to critical organs and structures within the limited space of the retroperitoneum and intra-abdominal cavity3

  • Repeat surgeries may be warranted in case of recurrences, and negative prognostic factors can include the extent of organ resection during the initial surgery, patient's age at the time of the second surgery, multifocality during the second surgery, incomplete resection in previous surgery, and histological characteristics of DDLPS3

  • Anthracycline-based chemotherapy is the current standard of care for systemic therapy and is not associated with ideal treatment outcomes1,2

Graphic showing response rate to treatment for DDLPS treated with anthracycline based chemotherapy is <=15%.
Image showing median overall survival (mOS) varies between ~8-12 months for anthracycline-based chemotherapy in STS
Graphic displaying the median progression free survival (mPFS) is approximately 2 to 5 months for STS treated with anthracycline based chemotherapy.

*Results from anthracycline-based chemotherapy.1

The standard of care in locally advanced 
(unresectable) and/or metastatic DDLPS has not 
changed significantly in approximately 5 decades1,2,6

A patient with DDLPS looking out over a forest and mountains

The importance of a multidisciplinary approach

A team of experts. A personalized approach in the management of DDLPS

  • A multidisciplinary team plays an important role in the diagnosis and management of a rare STS subtype such as DDLPS7,8

It takes a team to take on DDLPS7,8

A graphic showing the multidisciplinary team approach to DDLPS with a medical oncologist, surgical oncologist, sarcoma pathologist and radiologists and a radiation oncologist

Boehringer Ingelheim Oncology is taking a diligent 
and broad approach in some of the most 
challenging, but potentially most impactful, areas of 
cancer research.

mOS=median overall survival; mPFS=median progression-free survival; STS=soft tissue sarcoma.

References:

  1. Italiano A. Cancer Discov. 2023;13(8):1765-1767.

  2. McGovern Y, Zhou CD, Jones RL. Front Oncol. 2017;7:292. doi:10.3389/fonc.2017.00292

  3. Dominguez DA, Sampath S, Agulnik M, et al. Curr Oncol. 2023;30(5):4618-4631.

  4. Judson I, Radford JA, Harris M, et al. Eur J Cancer. 2001;37(7):870-877.

  5. Judson I, Verweij J, Gelderblom H, et al. Lancet Oncol. 2014;15(4):415-423.

  6. Gahvari Z, Parkes A. Curr Treat Options Oncol. 2020;21(2):15. doi:10.1007/s11864-020-0705-7

  7. Gamboa AC, Gronchi A, Cardona K. CA Cancer J Clin. 2020;70(3):200-229.

  8. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 25, 2023. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.